Evidence map›Paper›PMID 33025069›Full record

ReviewCurrent atherosclerosis reports2020

Intra-coronary Imaging for the Evaluation of Plaque Modifications Induced by Drug Therapies for Secondary Prevention.

Ismail Dogu Kilic, Enrico Fabris, Elvin Kedhi, Liviu-Nicolae Ghilencea, Gianluca Caiazzo, Sara Abou Sherif, Carlo Di Mario

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current atherosclerosis reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 7 institutions in 5 countries.

Ismail Dogu KilicDepartment of Cardiology, Pamukkale University Hospitals, Denizli, Turkey.
Enrico FabrisCardiovascular Department, University of Trieste, Trieste, Italy. enrico.fabris@hotmail.it.ORCID 0000-0001-9458-0736
Elvin KedhiDepartment of Cardiology, Isala Heart Center, Zwolle, the Netherlands.
Liviu-Nicolae GhilenceaUniversity of Medicine and Pharmacy Carol Davila, Bucharest, Romania.
Gianluca CaiazzoP.O. San Giuseppe Moscati, Aversa, Italy.
Sara Abou SherifBrighton and Sussex Medical School, Brighton, UK.
Carlo Di MarioCardio-toraco-vascular Department, Careggi University Hospital, Florence, Italy.
Azienda Ospedaliera S.Giuseppe Moscati · ITAzienda Ospedaliero-Universitaria Careggi · ITBrighton and Sussex Medical School · GBCarol Davila University of Medicine and Pharmacy · ROIsala · NLPamukkale University · TRUniversity of Trieste · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewPatients diagnosed with coronary artery disease are at a high risk of subsequent cardiovascular events; therefore, secondary prevention in the form of therapeutic lifestyle changes, and drug therapies is vital. This article aims to review potential application of intra-coronary imaging for the evaluation of plaque modifications, induced by medications for secondary prevention for CAD. RECENT

findingsIntra-coronary imaging provides detailed information on the atherosclerotic plaque which is the primary pathological substrate for the recurrent ischemic cardiovascular events. These modalities can detect features associated with high risk and allow serial in vivo imaging of lesions. Therefore, intravascular imaging tools have been used in landmark studies and played a role in improving our understanding of the disease processes. Changes in size and plaque composition over time can be evaluated by these tools and may help understanding the impact of a treatment. Moreover, surrogate imaging end points can be used when testing new drugs for secondary prevention.

Indexed as

PCSK9 InhibitorsSecondary PreventionBlood Component RemovalCholesterol, HDLCoronary Artery DiseaseHumansHydroxymethylglutaryl-CoA Reductase InhibitorsPlaque, AtheroscleroticProprotein Convertase 9Protease InhibitorsUltrasonography, InterventionalCholesterol, HDLHydroxymethylglutaryl-CoA Reductase InhibitorsPCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9Protease InhibitorsCoronary artery diseaseCoronary atherosclerosisIntra-coronary imagingSecondary preventionVulnerable plaque

Identifiers

PMID33025069
PMCPMC7538414
OpenAlexW3092539584

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.